Anticardiolipin and anti-β2 glycoprotein I antibody concentrations in patients with type 2 diabetes mellitus

Anticardiolipin Antibodies in Patients with Type 2 Diabetes Mellitus

“…3 In a series of 46 patients with type 2 diabetes mellitus, no case had an IgG ACA titer higher than 20 GPL units. 8 On the contrary, in a series of 21 patients with type 2 DM, an IgG ACA titer equal to or higher than 15 GPL was present in 9.5% of cases. 6 We find low IgG ACA titers (4-15 GPL units) in about onethird of our patients and low IgM ACA titers (4-15 MPL units) in about 10% of our patients.…”

“…Other studies describe no association between ACA and retinopathy or nephropathy. 3,8 Our study has several limitations, such as the study design did not include a healthy controls group, the low number of study subjects, and that we were not able to analyze other antiphospholipid antibodies (lupus anticoagulant and anti-beta-2 glycoprotein I antibodies). Moreover, we were not able to study the presence of neuropathy in all patients.…”

“…2 Previous data reflect controversy about an increased prevalence of antiphospholipid antibodies in types 1 and 2 diabetic patients, and the possible implications are little known. [3][4][5][6][7][8] We studied the presence of IgG and IgM ACA in a series of patients with type 2 DM.…”

Cardiovascular Biomarkers in Routine Screening of Diabetic Pati ents

“…Indeed, there is large body of evidence regarding coronary artery calcified plaque, carotid artery intima-media thickness, elevated blood pressure, worse kidney function, prolonged QT interval, poor glycemic control, and albuminuria might predict all cause and CV mortality in the general population of patients with T2DM [2]. Therefore, patients with T2DM have higher incidence of macrovascular disease and thrombotic complications than the general population and individuals with known CV disease [3,4]. Indeed, epidemiologic analyses have exhibited a strong association between T2DM and micro-and macrovascular disease [4].…”

“…Vascular dysfunction caused by metabolic abnormalities in patients with T2DM is associated with accelerated atherosclerosis and increased risk of myocardial infarction (MI), stroke, and peripheral arterial disease. Patients with T2DM are at two to four fold higher CV risk as compared to non-diabetic individuals [2][3][4]. The Canadian Primary Care Sentinel Surveillance Network (CPCSSN), which is a multi-disease surveillance system based on primary care electronic medical record data, has revealed that large proportion (65%) of T2DM patients without established atherosclerotic CV disease presented with 2 or more CV risk factors including: hypertension (62%), dyslipidemia (33%), active smoking (13%), and obesity (43%) [5].…”